Check out your Company Bowl for anonymous work chats.
Looking for opportunities to advance your career in oncology research? Check this out: http://glassdoor.com/slink.htm?key=vQqXY
Today is the one-year anniversary of our FDA approval for previously treated adult patients with chronic Graft-versus-Host disease (cGVHD). This approval marks our first disease indication outside of oncology. Learn more about our mission in striving to bring the Magic of Normal to their every day lives: http://glassdoor.com/slink.htm?key=vQmDn
Throughout the summer, our interns learn from top experts in their field by attending various speaker series. The most recent one highlighted Juthamas Sukbuntherng, Head of Clinical Pharmacology and Drug Metabolism & Pharmacokinetics.
Check out our press release on new data regarding the potential cellular-level intervention for adult patients with chronic Graft-Versus-Host-Disease #cGHVD: http://glassdoor.com/slink.htm?key=vQLgW
Check out our latest press release on 3.5 year follow-up data in Mantle Cell Lymphoma: http://glassdoor.com/slink.htm?key=vQLgg
Read our press release at #ASH17 on 3 year follow-up data on patients with Chronic Lymphocytic Leukemia: http://glassdoor.com/slink.htm?key=vQLg2
Today, the U.S. FDA approved a new therapy for a possible stem cell / bone marrow transplant complication when systemic therapy fails: http://glassdoor.com/slink.htm?key=vQ4qF
Dr. Ogden Bruton discovered the BTK enzyme in the early 1950s when he noticed a young boy had recurring lung infections. Testing revealed that the boy had no antibodies in his blood stream, making it difficult for his body to fight infection. Learn more about Dr. Bruton’s discovery and the BTK enzyme: http://glassdoor.com/slink.htm?key=vQ42h
